Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
BMJ Global Health|February 20, 2026
Drug-resistant tuberculosis in war and complex emergencies: jeopardising progress towards TB elimination and antimicrobial resistance control - a scoping review and perspectiveIgnacio Monedero-Recuero, Xiaolin Wei, Fabienne Jouberton, et al.
The New England Journal of Medicine|December 18, 2024
Levofloxacin Preventive Treatment in Children Exposed to MDR TuberculosisAnneke C Hesseling, Susan E Purchase, Neil A Martinson, et al.
The New England Journal of Medicine|March 14, 2019
A Trial of a Shorter Regimen for Rifampin-Resistant TuberculosisAndrew J Nunn, Patrick P J Phillips, Sarah K Meredith, et al.
The Lancet. Respiratory Medicine|November 17, 2019
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trialConor D Tweed, Rodney Dawson, Divan A Burger, et al.
The Lancet. Infectious Diseases|November 15, 2021
Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal studyNazir Ahmed Ismail, Shaheed Vally Omar, Harry Moultrie, et al.
Southern African Journal of HIV Medicine|March 24, 2018
South African HIV self-testing policy and guidance considerationsFrancois Venter, Mohammed Majam, Lauren Jankelowitz, et al.
Lancet (London, England)|November 11, 2022
Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trialRuth L Goodall, Sarah K Meredith, Andrew J Nunn, et al.
The Lancet. Respiratory Medicine|October 4, 2024
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trialRuth L Goodall, Andrew J Nunn, Sarah K Meredith, et al.
The New England Journal of Medicine|September 2, 2022
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant TuberculosisFrancesca Conradie, Tatevik R Bagdasaryan, Sergey Borisov, et al.
The New England Journal of Medicine|October 15, 2010
Antiretroviral therapies in women after single-dose nevirapine exposureShahin Lockman, Michael D Hughes, James McIntyre, et al.
Pageof 7